French President Francois Hollande, faced with a rebellion within his ruling Socialist Party, dissolved his cabinet and swore to start afresh. Hollande’s popularity rating is only 17 percent
The new Roamio OTA costs $50, plus $15 per month
The founder of a Hong Kong democracy movement has kicked off a furor by saying he would welcome police use of tear gas and water cannon to suppress a possible march by activists
In the biggest acquisition in Amazon's history, the online retailer pays $970 million for Twitch, which Googled courted for months
It’s a psychological threshold, but the 2K mark has no particular significance for buy-and-hold investors
A human cannot copyright the work of an animal—or, for that matter, the ocean
With its new site, Like2Buy, Nordstrom wants to make shopping easier for Instagram followers
Before students at Stanford's business school arrive on campus, most of them will spend a week together in Colombia on a trip that has become an unwritten tradition at the school
Small independent vintners who stored wine barrels in shared facilities were closer to the California earthquake's epicenter
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.